Der Onkologe

, Volume 19, Issue 5, pp 363–370 | Cite as

Pathologie des ösophagogastralen Adenokarzinoms

Von der Karzinogenese zur molekularen Therapie
Leitthema
  • 363 Downloads

Zusammenfassung

Hintergrund

Adenokarzinome des ösophagogastralen Übergangs (AEG) und des Magens weisen vergleichbare Vorläuferläsionen und genetische Veränderungen auf, haben aber ein unterschiedliches Risikoprofil und verschiedene epidemiologische Charakteristika.

Ziel

Im folgenden Beitrag werden die pathohistologischen und molekularen Unterschiede sowie Gemeinsamkeiten der beiden Entitäten auch in Bezug auf ihre therapeutischen Optionen verglichen.

Material und Methode

Es wurde eine Literaturrecherche zum Themenkomplex Adenokarzinom des ösophagogastralen Übergangs und Magens hinsichtlich pathohistologischer und molekularer sowie klinischer Charakteristika durchgeführt.

Ergebnisse

Auf molekularer Ebene weisen Adenokarzinome der beiden Lokalisationen vergleichbare Veränderungen auf, die teilweise auch mit dem histologischen Subtyp korrelieren.

Schlussfolgerung

Neben Gemeinsamkeiten besonders in der formalen Pathogenese ist die unterschiedliche, lokalisationsabhängige, von der WHO empfohlene Tumorklassifikation von wesentlicher klinischer Bedeutung. Als molekulare Targets im Rahmen der Therapieoptimierung sind HER2/neu und für die Zukunft möglicherweise c-MET zu nennen.

Schlüsselwörter

Magenkarzinom Laurén-Klassifikation Karzinogenese Molekularbiologie TNM-Klassifikation 

Pathology of esophagogastric adenocarcinomas

From carcinogenesis to molecular therapy

Abstract

Context

Adenocarcinomas of the esophagogastric junction and the stomach share similar preneoplastic lesions and genetic alterations but are different according to their risk profiles and epidemiological characteristics.

Objective

The aim of the review was the comparison of pathohistological, molecular and therapeutic similarities and differences of these tumor entities.

Material and methods

The following review relied on a literature database search comprising the pathohistological, molecular and clinical characteristics of adenocarcinomas of the esophagogastric junction and the stomach.

Results

For both entities comparable alterations have been published even correlating with the pathohistological subtypes.

Conclusions

Despite many similarities concerning pathogenesis, the TNM classification for both tumor entities recommended by the WHO depends on the localization and is of particular importance for the clinical practice. Molecular targets for therapy optimization include Her2/neu and in the future, perhaps also c-Met.

Keywords

Gastric cancer Laurén classification Carcinogenesis Molecular biology TNM classification 

Notes

Interessenkonflikt

Die korrespondierende Autorin gibt für sich und ihre Koautoren an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Agarwal A, Polineni R, Hussein Z et al (2012) Role of epigenetic alterations in the pathogenesis of Barrett’s esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol 5:382–396PubMedGoogle Scholar
  2. 2.
    Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRefGoogle Scholar
  3. 3.
    Bollschweiler E, Baldus SE, Schroder W et al (2006) Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol 94:355–363PubMedCrossRefGoogle Scholar
  4. 4.
    Bosman FT, Carneiro F, Hruban RH (Hrsg) (2010) WHO classification of tumours of the digestive system. World Health OrgnGoogle Scholar
  5. 5.
    Carneiro F (2012) Hereditary gastric cancer. Pathologe 33(Suppl 2):231–234PubMedCrossRefGoogle Scholar
  6. 6.
    Correa P (1988) A human model of gastric carcinogenesis. Cancer Res 48:3554–3560PubMedGoogle Scholar
  7. 7.
    Deng N, Goh LK, Wang H et al (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673–684PubMedCrossRefGoogle Scholar
  8. 8.
    Giaginis CT, Vgenopoulou S, Tsourouflis GS et al (2009) Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res 15:173–181PubMedCrossRefGoogle Scholar
  9. 9.
    Hahn HP, Blount PL, Ayub K et al (2009) Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol 33:1006–1015PubMedCrossRefGoogle Scholar
  10. 10.
    Hattori T, Mukaisho K, Miwa K (2005) Pathogenesis of Barrett’s esophagus–new findings in the experimental studies of duodenal reflux models. Nihon Rinsho 63:1341–1349PubMedGoogle Scholar
  11. 11.
    Hvid-Jensen F, Pedersen L, Drewes AM et al (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383PubMedCrossRefGoogle Scholar
  12. 12.
    Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMedGoogle Scholar
  13. 13.
    Lennerz JK, Kwak EL, Ackerman A et al (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803–4810PubMedCrossRefGoogle Scholar
  14. 14.
    Liu L, Hofstetter WL, Rashid A et al (2005) Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 29:1079–1085PubMedGoogle Scholar
  15. 15.
    Möhler M, Ebert M, Galle PR et al (2011) S3-Leitlinie Magenkarzinom: Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. S3-Leitlinie „Magenkarzinom“ – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist.-Nr. 032-009-OL) German S3-Guideline „Diagnosis and Treatment of Esophagogastric Cancer“. Z Gastroenterol 49:461–531CrossRefGoogle Scholar
  16. 16.
    Nakajima S, Hattori T (2003) Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy. Helicobacter 8:279–293PubMedCrossRefGoogle Scholar
  17. 17.
    Ruschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307PubMedCrossRefGoogle Scholar
  18. 18.
    Shah MA, Khanin R, Tang L et al (2011) Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 17:2693–2701PubMedCrossRefGoogle Scholar
  19. 19.
    Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459PubMedCrossRefGoogle Scholar
  20. 20.
    Sikkema M, Kerkhof M, Steyerberg EW et al (2009) Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case-control study. Am J Gastroenterol 104:2673–2680PubMedCrossRefGoogle Scholar
  21. 21.
    Su Z, Gay LJ, Strange A et al (2012) Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat Genet 44:1131–1136PubMedCrossRefGoogle Scholar
  22. 22.
    Tan IB, Ivanova T, Lim KH et al (2011) Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141:476–485, 485 e1–e11PubMedCrossRefGoogle Scholar
  23. 23.
    Varghese S, Lao-Sirieix P, Fitzgerald RC (2012) Identification and clinical implementation of biomarkers for Barrett’s esophagus. Gastroenterology 142:435–441 e432PubMedCrossRefGoogle Scholar
  24. 24.
    Wang JS, Guo M, Montgomery EA et al (2009) DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett’s esophagus. Am J Gastroenterol 104:2153–2160PubMedCrossRefGoogle Scholar
  25. 25.
    Westerterp M, Koppert LB, Buskens CJ et al (2005) Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 446:497–504PubMedCrossRefGoogle Scholar
  26. 26.
    Wittekind C, Meyer HJ (2010) TNM-Klassifikation maligner Tumore. Wiley-Blackwell, WeinheimGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Institut für PathologieRuhr-Universität BochumBochumDeutschland

Personalised recommendations